Literature DB >> 11028941

Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization.

P O'Hara1, A J Hickey.   

Abstract

PURPOSE: Particles with aerodynamic diameters of 1-5 microm deposit in the periphery of the lungs and are phagocytized by alveolar macrophages, the primary site of Mycobacterium tuberculosis infection. Aerosols of biodegradable polymeric microspheres containing antitubercular agents may be delivered to the lungs to improve the treatment of tuberculosis.
METHODS: Poly(lactide-co-glycolide) (PLGA) microspheres containing rifampicin were prepared using solvent evaporation and spray drying methods. The solvent evaporation process was optimized using factorial experimental design and surface response methodology. The morphology, particle size, drug loading, and dissolution of microspheres was evaluated.
RESULTS: The spray dried rifampicin loaded PLGA microparticles were shriveled, unlike the spherical particles produced by solvent evaporation. Drug loadings of 20% and 30% were achieved for solvent evaporation and spray dried products, respectively. The particles prepared by solvent evaporation and spray drying had 3.45 microm and 2.76 microm median diameters by volume, respectively.
CONCLUSIONS: Respirable rifampicin loaded PLGA microspheres were produced by both solvent evaporation and spray drying methods. These particles are being evaluated in an animal model of tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11028941     DOI: 10.1023/a:1007527204887

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  12 in total

1.  Effect of processing parameters on the properties of peptide-containing PLGA microspheres.

Authors:  R Jeyanthi; R C Mehta; B C Thanoo; P P DeLuca
Journal:  J Microencapsul       Date:  1997 Mar-Apr       Impact factor: 3.142

Review 2.  Metabolism and pharmacokinetics of the antibiotic rifampin.

Authors:  M T Kenny; B Strates
Journal:  Drug Metab Rev       Date:  1981       Impact factor: 4.518

3.  In vitro and in vivo degradation of poly(D,L lactide/glycolide) type microspheres made by solvent evaporation method.

Authors:  G Spenlehauer; M Vert; J P Benoit; A Boddaert
Journal:  Biomaterials       Date:  1989-10       Impact factor: 12.479

4.  Rifampicin carrying poly (D,L-lactide)/poly(ethylene glycol) microspheres: loading and release.

Authors:  E Celikkaya; E B Denkbaş; E Pişkin
Journal:  Artif Organs       Date:  1996-07       Impact factor: 3.094

5.  Piroxicam release from spray-dried biodegradable microspheres.

Authors:  B W Wagenaar; B W Müller
Journal:  Biomaterials       Date:  1994-01       Impact factor: 12.479

6.  A new long-acting injectable microcapsule system for the administration of progesterone.

Authors:  L R Beck; D R Cowsar; D H Lewis; R J Cosgrove; C T Riddle; S L Lowry; T Epperly
Journal:  Fertil Steril       Date:  1979-05       Impact factor: 7.329

7.  High-pressure liquid chromatographic quantitation of rifampin and its two major metabolites in urine and serum.

Authors:  A Weber; K E Opheim; A L Smith; K Wong
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

8.  Biodegradable microspheres of poly(DL-lactic acid) containing piroxicam as a model drug for controlled release via the parenteral route.

Authors:  J K Lalla; K Sapna
Journal:  J Microencapsul       Date:  1993 Oct-Dec       Impact factor: 3.142

9.  Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages.

Authors:  E L Barrow; G A Winchester; J K Staas; D C Quenelle; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Rifampicin-carrying poly(D,L-lactide) microspheres: loading and release.

Authors:  E B Denkbaş; X Kaitian; A Tuncel; E Pişkin
Journal:  J Biomater Sci Polym Ed       Date:  1995       Impact factor: 3.517

View more
  44 in total

1.  Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.

Authors:  Vasu V Sethuraman; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2002       Impact factor: 3.246

2.  Building membrane emulsification into pulmonary drug delivery and targeting.

Authors:  Decai Bao; Yanjun Zhao
Journal:  Pharm Res       Date:  2010-08-12       Impact factor: 4.200

Review 3.  Particle engineering for pulmonary drug delivery.

Authors:  Albert H L Chow; Henry H Y Tong; Pratibhash Chattopadhyay; Boris Y Shekunov
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

Review 4.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

5.  Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity.

Authors:  Awadh Bihari Yadav; Amit Misra
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

6.  Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice.

Authors:  Rahul Kumar Verma; Jatinder Kaur; Kaushlendra Kumar; Awadh Bihari Yadav; Amit Misra
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

Review 7.  Inhaled drug delivery for tuberculosis therapy.

Authors:  Pavan Muttil; Chenchen Wang; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

8.  Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles.

Authors:  Takuto Mizoe; Tetsuya Ozeki; Hiroaki Okada
Journal:  AAPS PharmSciTech       Date:  2008-06-18       Impact factor: 3.246

9.  Formation of inhalable rifampicin-poly(L-lactide) microparticles by supercritical anti-solvent process.

Authors:  Vipaluk Patomchaiviwat; Ornlaksana Paeratakul; Poj Kulvanich
Journal:  AAPS PharmSciTech       Date:  2008-11-07       Impact factor: 3.246

Review 10.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.